Table 3 Level of 25(OH)D in Healthy Subjects and Patients with malabsorption syndrome after 30 day administration of vitamin D3 buccal spray and soft gelatin capsule
Parameters | Mean baseline value in ng/ml | Mean value in ng/ml after 30 day of treatment | Difference of mean | Percentage mean increase from baseline |
|---|---|---|---|---|
Healthy Subjects | ||||
Soft gelatin Capsule Formulation | ||||
Mean | 18.69 ± 5.88 | 22.75 ± 6.75 | 4.06 | 21.72 % |
Range | 9.25, 30.05 | 12.75, 35.52 | 2.5, 5.6 | 15.36, 37.79 |
n | 13 | 13 | 13 | 13 |
95 % CI | 15.14 to 22.24 | 18.67 to 24.42 | 3.41 to 4.71 | 16.42 to 24.42 |
Buccal Spray Formulation | ||||
Mean | 18.91 ± 4.3 | 26.91 ± 5.72 | 7.995 | 42.99 % |
Range | 13.36, 26.82 | 19.6, 38.5 | 4.5, 11.67 | 29.21, 68.71 |
n | 13 | 13 | 13 | 13 |
95 % CI | 16.31 to 21.51 | 23.45 to 30.36 | 6.86 to 9.13 | 37.19 to 48.79 |
Patients with intestinal malabsorption syndrome | ||||
Soft gelatin Capsule Formulation | ||||
Mean | 11.01 ± 6.43 | 14.97 ± 9.01 | 3.965 | 36.02 % |
Range | 2.9, 26.5 | 4.6, 36.89 | 1.06,10.39 | 24.62,58.73 |
n | 13 | 13 | 13 | 13 |
95 % CI | 7.12 to 14.89 | 9.52 to 20.42 | 2.37 to 5.56 | 30.42 to 41.62 |
Buccal Spray Formulation | ||||
Mean | 10.01 ± 4.29 | 20.47 ± 7.89 | 10.46 | 117.8 % |
Range | 4.6, 18.85 | 9.8, 34.64 | 4.25, 27.44 | 61.31,381.1 |
n | 13 | 13 | 13 | 13 |
95 % CI | 7.42 to 12.6 | 15.7 to 25.24 | 6.89 to 14.03 | 64.71 to 170.8 |